Drugs Made In America Acquisition II Corp. reported net income of $4.34M for the first quarter of 2026, a turnaround from a loss of ($59K) in the year-ago quarter; diluted earnings per share were $0.07 versus ($0) in Q1 2025. The company has not commenced operations and reported no operating revenue for the period.
Financial Highlights
- Net income was $4.34M for Q1 2026, versus ($59K) in Q1 2025 (turnaround to profit).
- Diluted EPS was $0.07 for Q1 2026 (diluted), versus ($0.00) for Q1 2025.
- Revenue: Not reported for Q1 2026 (Company has not commenced operations; interest income is non-operating).
Business Highlights
- Business focus: blank-check company targeting pharmaceutical industry acquisitions and seeking a strategic combination.
- Capital formation: completed IPO and private placement and placed approximately $500M net proceeds in a trust to fund an initial business combination.
- Operational activity: no operating revenues; post-IPO activities limited to target identification, due diligence and transaction preparation.
- Governance timeline: a 24-month Combination Period to complete a business combination; failure to do so would trigger liquidation and shareholder redemptions.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.